Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene : Scripps hopes for royalty windfall from potential blockbuster drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/11/2017 | 12:54am CET

Nov. 10--If the new drug ozanimod achieves blockbuster status, it could generate tens of millions of dollars a year in royalties for the Scripps Research Institute -- and provide relief from the ongoing financial challenges facing the nonprofit lab.

Scripps won't say how much it stands to receive from sales of ozanimod, a drug that slows brain atrophy in patients with multiple sclerosis. Scripps discovered the drug, then partnered with Celgene to shepherd the medicine through clinical trials. The biopharmaceutical company expects to begin marketing the drug to MS patients in late 2018.

Celgene (Nasdaq: CELG) also is testing ozanimod as a treatment for ulcerative colitis, which is more common than MS. If ozanimod wins approval as a medicine for the intestinal disorder, sales could reach $4 billion to $6 billion a year.

Scripps says its royalty arrangement with Celgene is confidential. Brian Skorney, an analyst who follows Celgene for Robert W. Baird & Co., said the typical deal pays a drug's inventor "in the low single-digit percentage."

So, if ozanimod's sales reach $4 billion and Scripps gets a 2 percent cut, that would amount to $80 million a year. It would be a welcome windfall for Scripps, which has seen its revenue decline steadily in recent years.

The nonprofit lab's revenue fell to $347.5 million for the year ended Sept. 30, 2016, according to a financial statement, down from $362.5 million the previous year.

It was the fifth consecutive year of declining revenue for San Diego-based Scripps, the scientific juggernaut that's the anchor of Florida's billion-dollar bet on biotech. Scripps in 2016 reported its lowest annual revenue since 2004.

Scripps' net assets dipped to $637 million, down from $647 million in 2015 and the lowest level since 2007.

Dr. Hugh Rosen, a Scripps researcher who's the co-inventor of ozanimod, said the institute's agreement with Celgene calls for royalty payments through 2033 or 2034.

"It could be a significant contributor to the health of the institution," Rosen said.

Patient studies proved that ozanimod is safe and effective, but it's still no sure thing. Skorney said ozanimod faces competition from other MS drugs.

"It's a very crowded space in terms of the number of effective treatments, so we'll see how Celgene ends up pricing it," Skorney said.

Rosen said ozanimod's journey from the lab to the doctor's office underscores the long-term nature of scientific research. In 2002, he started the work that led to ozanimod, and a flurry of tests from 2006 to 2008 ultimately yielded the new drug.

"It will be literally 10 years from discovery to launch for patients, and that's about as fast as you could hope for," Rosen said.


(c)2017 The Palm Beach Post (West Palm Beach, Fla.)

Visit The Palm Beach Post (West Palm Beach, Fla.) at www.palmbeachpost.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 CELGENE : Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen f..
01/19 BeiGene raises $750M follow-on in busy month
01/19 CELGENE : to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of N..
01/19 CELGENE : New Findings from Celgene in the Area of Breast Cancer Reported (Outco..
01/18 CELGENE : rumoured to be revving up for Juno buyout
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTICS : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
More news
News from SeekingAlpha
07:59a YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Key events next week - healthcare
01/19 ROTY EDITION 1 VOLUME 71 : Thoughts On A Juno Buyout, Outperformance Continues A..
01/19 JUNO THERAPEUTICS : What The Celgene Potential Acquisition Foretells
01/19 BELLICUM PHARMACEUTICALS : CAR-T Play With Catalysts In 2018
Financials ($)
Sales 2017 12 981 M
EBIT 2017 7 490 M
Net income 2017 4 448 M
Debt 2017 5 265 M
Yield 2017 -
P/E ratio 2017 18,40
P/E ratio 2018 14,39
EV / Sales 2017 6,63x
EV / Sales 2018 5,41x
Capitalization 80 818 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 124 $
Spread / Average Target 21%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132